Gilead Stock News

The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 867 13F filings that hedge funds and well-known value investors are required to file by the SEC.

Earnings updates from Gilead (GILD) and regulatory updates are among a few key highlights from the biotech sector during the past week.

Gilead (GILD) misses on earnings but beats on sales in the fourth quarter. While the HIV business maintains momentum on Biktarvy, sales of Veklury decline.

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus LogicBio Phase 1/2 Study Of Genome Editing Therapy In Methylmalonic Acidemia Placed On Clinical Hold L

Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus LogicBio Phase 1/2 Study Of Genome Editing Therapy In Methylmalonic Acidemia Placed On Clinical Hold LogicBio Therapeutics, Inc. (NASDAQ: LOGC ) announced the U.S. Food and Drug Administration has notified the company that its Phase 1/2 SUNRISE clinical trial of LB-001 in pediatric patients with methylmalonic acidemia has been placed on clinical hold. LB-001 is LogicBio''s investigational, single-administration, adeno-associated virus genome editing therapy. The company noted as reported earlier, the third patient dosed in the SUNRISE trial, who is in the younger age group of 6 months to 2 years old, experienced a drug-related serious adverse event, which was categorized as a case of thrombotic microangiopathy. The stock was sliding 16% to $1.26 in premarket trading. Click here to access Benzinga''s FDA Calendar Atea Announces Publication Of Positive Data On Investigational COVID-19 Treatment Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) announced the publication in the peer-reviewed journal "Nature Communications" new data demonstrating bemnifosbuvir''s unique mechanism of action that provides the potential to create a high barrier to resistance with broad antiviral activity across SARS-CoV-2 variants of concern.

GlaxoSmithKline plc GSK has settled a patent dispute between ViiV Healthcare and Gilead Sciences Inc GILD. Thousands of new traders are learning the ins and outs on how to find profitable trades ev

Gilead (GILD) misses on earnings but beats on sales in the fourth quarter. While the HIV business maintains momentum on Biktarvy, sales of Veklury decline.

Gilead Sciences Inc (NASDAQ: GILD ) posted Q4 FY21 adjusted EPS of $0.69 , sharply below $2.19 posted a year ago. The company said that the earnings included $1.25 billion related to a legal settlement and $625 million related to the Arcus collaboration opt-in, representing an unfavorable impact of $0.80 and $0.38, respectively. 4Q FY21 revenue of $7.2 billion decreased 2% Y/Y, surpassing the consensus of $6.64 billion. Veklury (remdesivir 100 mg for injection) product sales declined 30% Y/Y to $1.4 billion, generally affected by Full story available on Benzinga.com

GILD earnings call for the period ending December 31, 2021.

GILD earnings call for the period ending December 31, 2021.

Gilead Sciences Inc GILD posted Q4 FY21 adjusted EPS of $0.69, sharply below $2.19 posted a year ago. Thousands of new traders are learning the ins and outs on how to find profitable trades every da

GlaxoSmithKline (GSK) announced that ViiV Healthcare, majority-owned by the U.K